# ENZAMET (NCT02446405)

> Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02446405
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Sydney
- Conditions: Prostatic Neoplasms
- Interventions: Enzalutamide; NSAA; LHRHA or Surgical Castration
- Enrollment: 1125
- Primary outcome: Overall Survival Time

## Commentary we found

- X threads: 112
- Podcasts: 44
- YouTube: 43
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=enzamet-nct02446405

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02446405", "email": "<work email>"}; the inbox owner confirms by the emailed link.